Class information for:
Level 1: FULVESTRANT//ENDOCRINE RESISTANCE//FASLODEX

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
7620 1347 49.5 88%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
159 3       MENOPAUSE//ISOFLAVONES//TAMOXIFEN 61134
329 2             TAMOXIFEN//ESTROGEN RECEPTOR//AROMATASE INHIBITORS 18133
7620 1                   FULVESTRANT//ENDOCRINE RESISTANCE//FASLODEX 1347

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 FULVESTRANT authKW 2070837 11% 61% 149
2 ENDOCRINE RESISTANCE authKW 777386 6% 46% 75
3 FASLODEX authKW 372804 2% 66% 25
4 ENDOCRINE THERAPY authKW 353606 8% 15% 104
5 ADVANCED BREAST CANCER authKW 221774 5% 15% 66
6 TENOVUS CANC address 211916 3% 27% 35
7 HLTH SCI IL 1 address 161332 1% 65% 11
8 TUMOR ENDOCRINOL address 148756 1% 35% 19
9 TAMOXIFEN RESISTANCE authKW 138698 2% 20% 31
10 HORMONE RECEPTOR POSITIVE authKW 127486 1% 38% 15

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 22691 66% 0% 892
2 Endocrinology & Metabolism 2080 16% 0% 216
3 Cell Biology 378 10% 0% 141
4 Biochemistry & Molecular Biology 220 15% 0% 202
5 Obstetrics & Gynecology 166 4% 0% 56
6 Pharmacology & Pharmacy 35 6% 0% 78
7 Medicine, Research & Experimental 15 3% 0% 34
8 Genetics & Heredity 13 3% 0% 38
9 Chemistry, Medicinal 12 2% 0% 23
10 Health Care Sciences & Services 1 1% 0% 9

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TENOVUS CANC 211916 3% 27% 35
2 HLTH SCI IL 1 161332 1% 65% 11
3 TUMOR ENDOCRINOL 148756 1% 35% 19
4 BREAST CANC GRP 103553 1% 24% 19
5 MOL FUNCT DYNAM 94436 1% 42% 10
6 CELL DEATH METAB 85328 1% 47% 8
7 LESTER SUE SMITH BREAST 72290 2% 11% 30
8 ENTRY MED HLTH GEMS 68003 0% 100% 3
9 SERV MEM 120 68003 0% 100% 3
10 NK BASILE CANC BREAST EXCELLENCE 51000 0% 75% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BREAST CANCER RESEARCH AND TREATMENT 33833 8% 1% 104
2 ENDOCRINE-RELATED CANCER 31540 4% 3% 48
3 BREAST CANCER RESEARCH 17495 3% 2% 41
4 CLINICAL BREAST CANCER 12992 2% 3% 21
5 CLINICAL CANCER RESEARCH 7200 5% 0% 69
6 MOLECULAR ENDOCRINOLOGY 6079 3% 1% 39
7 JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 5978 4% 1% 49
8 BREAST 5361 2% 1% 24
9 BREAST CARE 3957 1% 2% 10
10 CANCER TREATMENT REVIEWS 2264 1% 1% 14

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 FULVESTRANT 2070837 11% 61% 149 Search FULVESTRANT Search FULVESTRANT
2 ENDOCRINE RESISTANCE 777386 6% 46% 75 Search ENDOCRINE+RESISTANCE Search ENDOCRINE+RESISTANCE
3 FASLODEX 372804 2% 66% 25 Search FASLODEX Search FASLODEX
4 ENDOCRINE THERAPY 353606 8% 15% 104 Search ENDOCRINE+THERAPY Search ENDOCRINE+THERAPY
5 ADVANCED BREAST CANCER 221774 5% 15% 66 Search ADVANCED+BREAST+CANCER Search ADVANCED+BREAST+CANCER
6 TAMOXIFEN RESISTANCE 138698 2% 20% 31 Search TAMOXIFEN+RESISTANCE Search TAMOXIFEN+RESISTANCE
7 HORMONE RECEPTOR POSITIVE 127486 1% 38% 15 Search HORMONE+RECEPTOR+POSITIVE Search HORMONE+RECEPTOR+POSITIVE
8 ESTROGEN RECEPTOR 115917 14% 3% 185 Search ESTROGEN+RECEPTOR Search ESTROGEN+RECEPTOR
9 EVEROLIMUS 100206 5% 6% 74 Search EVEROLIMUS Search EVEROLIMUS
10 LMTK3 94446 0% 83% 5 Search LMTK3 Search LMTK3

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 AGRAWAL, A , ROBERTSON, JFR , CHEUNG, KL , GUTTERIDGE, E , ELLIS, IO , NICHOLSON, RI , GEE, JMW , (2016) BIOLOGICAL EFFECTS OF FULVESTRANT ON ESTROGEN RECEPTOR POSITIVE HUMAN BREAST CANCER: SHORT, MEDIUM AND LONG-TERM EFFECTS BASED ON SEQUENTIAL BIOPSIES.INTERNATIONAL JOURNAL OF CANCER. VOL. 138. ISSUE 1. P. 146 -159 42 93% 3
2 MURPHY, LC , SEEKALLU, SV , WATSON, PH , (2011) CLINICAL SIGNIFICANCE OF ESTROGEN RECEPTOR PHOSPHORYLATION.ENDOCRINE-RELATED CANCER. VOL. 18. ISSUE 1. P. R1-R14 64 56% 54
3 KRELL, J , JANUSZEWSKI, A , YAN, K , PALMIERI, C , (2011) ROLE OF FULVESTRANT IN THE MANAGEMENT OF POSTMENOPAUSAL BREAST CANCER.EXPERT REVIEW OF ANTICANCER THERAPY. VOL. 11. ISSUE 11. P. 1641 -1652 47 85% 4
4 LE ROMANCER, M , POULARD, C , COHEN, P , SENTIS, S , RENOIR, JM , CORBO, L , (2011) CRACKING THE ESTROGEN RECEPTOR'S POSTTRANSLATIONAL CODE IN BREAST TUMORS.ENDOCRINE REVIEWS. VOL. 32. ISSUE 5. P. 597 -622 86 33% 76
5 CROXTALL, JD , MCKEAGE, K , (2011) FULVESTRANT A REVIEW OF ITS USE IN THE MANAGEMENT OF HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN.DRUGS. VOL. 71. ISSUE 3. P. 363-380 46 69% 28
6 GARCIA-BECERRA, R , SANTOS, N , DIAZ, L , CAMACHO, J , (2013) MECHANISMS OF RESISTANCE TO ENDOCRINE THERAPY IN BREAST CANCER: FOCUS ON SIGNALING PATHWAYS, MIRNAS AND GENETICALLY BASED RESISTANCE.INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. VOL. 14. ISSUE 1. P. 108 -145 76 30% 58
7 PEREZ, EA , (2016) TREATMENT STRATEGIES FOR ADVANCED HORMONE RECEPTOR-POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE BREAST CANCER: THE ROLE OF TREATMENT ORDER.DRUG RESISTANCE UPDATES. VOL. 24. ISSUE . P. 13 -22 39 62% 2
8 PLAZA-MENACHO, I , MORANDI, A , ROBERTSON, D , PANCHOLI, S , DRURY, S , DOWSETT, M , MARTIN, LA , ISACKE, CM , (2010) TARGETING THE RECEPTOR TYROSINE KINASE RET SENSITIZES BREAST CANCER CELLS TO TAMOXIFEN TREATMENT AND REVEALS A ROLE FOR RET IN ENDOCRINE RESISTANCE.ONCOGENE. VOL. 29. ISSUE 33. P. 4648 -4657 38 73% 50
9 NICOLINI, A , FERRARI, P , BIAVA, PM , CARPI, A , (2014) CHANGING THE ENDOCRINE DEPENDENCE OF BREAST CANCER: DATA AND HYPOTHESES.CURRENT MEDICINAL CHEMISTRY. VOL. 21. ISSUE 9. P. 1093 -1106 70 40% 1
10 BRUCE, MC , MCALLISTER, D , MURPHY, LC , (2014) THE KINOME ASSOCIATED WITH ESTROGEN RECEPTOR-POSITIVE STATUS IN HUMAN BREAST CANCER.ENDOCRINE-RELATED CANCER. VOL. 21. ISSUE 5. P. R357 -R370 64 43% 2

Classes with closest relation at Level 1


Rank Class id link
1 5771 ANTIESTROGEN//ANTIESTROGEN BINDING SITES//AEBS
2 6912 ESTROGEN RECEPTOR BETA//ER BETA//RECEPTOR BIOL SECT
3 9000 STEROID HORMONES SECT//AIB1//SRC 3
4 8689 GPR30//GPER//G 1
5 5097 AROMATASE INHIBITORS//ANASTROZOLE//EXEMESTANE
6 10644 ESTROGEN RECEPTOR//ESTROGEN RECEPTOR VARIANTS//TAMOXIFEN AZIRIDINE
7 4960 AROMATASE INHIBITORS//AROMATASE INHIBITOR//ANASTROZOLE
8 2563 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
9 32633 THIOSENS//PHARMACOL CELLULAIRE MOL ANTICANC//ALPHANIZOMENON FLOS AQUAE
10 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB

Go to start page